- Not yet recruiting
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma
iMMagine-1
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma
A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy.
Sponsor
Collaborator
Multiple Myeloma Research Foundation
ClinicalTrials.gov Identifier: NCT05396885
Official Title: A Phase II Study of CART-ddBMCA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma (iMMagine-1)
First Posted: May 31, 2022